Mission Statement, Vision, & Core Values of Arcturus Therapeutics Holdings Inc. (ARCT)

Ever wondered what drives a company focused on developing mRNA medicines and vaccines, especially when they've faced recent financial headwinds? Did you know that Arcturus Therapeutics reported a wider-than-expected loss for the fourth quarter of 2024, with an EPS of -$1.11, missing the forecast of -$0.19, and a revenue of $22.8 million against the expected $63.22 million? What are the core principles guiding their mission to create transformative RNA medicines, and how do these values shape their approach to innovation and patient care? Read on to explore the mission, vision, and core values that steer Arcturus Therapeutics.

Arcturus Therapeutics Holdings Inc. (ARCT) An Overview of

Arcturus Therapeutics Holdings Inc. is a global late-stage clinical messenger RNA medicines and vaccines company focused on developing infectious disease vaccines and significant opportunities within liver and respiratory diseases. Founded in 2013 and headquartered in San Diego, California, Arcturus leverages its proprietary LUNAR delivery platform and mRNA manufacturing capabilities to develop innovative therapies.

The company's pipeline includes mRNA-based vaccines for infectious diseases, as well as mRNA therapeutics for liver and respiratory diseases. Arcturus's commitment extends to addressing unmet needs across various therapeutic areas, marking it as a key player in advancing mRNA technologies for global health solutions.

Arcturus Therapeutics focuses on pioneering advancements in mRNA medicines and vaccines. Its primary products and services include:

• mRNA Vaccines: Development of vaccines for infectious diseases.
• mRNA Therapeutics: Creation of therapies for liver and respiratory diseases.
• LUNAR Delivery Platform: Utilizing its proprietary technology for effective drug delivery.
• Manufacturing Capabilities: Producing mRNA on a global scale.

For additional details on the company's background, explore Arcturus Therapeutics Holdings Inc. (ARCT): History, Ownership, Mission, How It Works & Makes Money.

Arcturus Therapeutics has demonstrated significant financial performance, particularly in 2024. The company reported a substantial increase in revenue, driven primarily by its mRNA vaccine programs and strategic collaborations.

Key highlights from the latest financial reports include:

• Record-Breaking Revenue: A significant increase in total revenue compared to the previous year, driven by milestone payments and research grants.
• mRNA Vaccine Sales: Strong performance in the sales of mRNA-based vaccines, reflecting growing market demand.
• Strategic Collaborations: Successful partnerships with leading pharmaceutical companies, contributing to revenue growth and pipeline expansion.
• Market Growth: Expansion into new geographical markets, further boosting sales and revenue.

Arcturus Therapeutics has established itself as a prominent leader in the mRNA technology space, driven by its innovative LUNAR delivery platform and comprehensive mRNA manufacturing capabilities. The company's focus on developing vaccines and therapeutics for infectious diseases, liver, and respiratory conditions positions it as a key player in addressing global health challenges.

To truly understand the factors behind Arcturus Therapeutics' success, delve deeper into its mission statement, vision, and core values. These elements provide critical insights into the company's strategic direction and operational philosophy.

Arcturus Therapeutics Holdings Inc. (ARCT) Mission Statement

Arcturus Therapeutics Holdings Inc. (ARCT), founded in 2013 and based in San Diego, California, is a commercial messenger RNA (mRNA) medicines and vaccines company. It focuses on the discovery, development, and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus specializes in RNA therapeutic technologies.

The company's mission is centered on developing and commercializing transformative RNA medicines for rare diseases and genetic disorders.

Key components of Arcturus Therapeutics' mission include:

• RNA Medicine Innovation: Specializing in RNA therapeutic technologies, including LUNAR and STARR delivery technologies.
• Technology Focus: Arcturus utilizes LUNAR and STARR platforms.
• Patent Portfolio: Arcturus has over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries.

Arcturus aims to address major hurdles in RNA development, specifically effective and safe delivery. The company’s key proprietary technology is geared toward addressing these challenges.

Arcturus' pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza.

The company’s financial performance for the full year 2024 includes:

• Revenue: $22.8 million in Q4, down from $30.9 million in Q4 2023. Annual revenue was $152.3 million, a decrease of $14.5 million from 2023.
• Net Loss: $30 million for Q4, translating to a loss of $1.11 per diluted share. The net loss for the full year was $80.94 million, compared to $29.73 million a year ago.
• Cash and Equivalents: $293.9 million as of December 31, 2024.
• R&D Expenses: $43.8 million in Q4 2024, up from $36.6 million in Q4 2023.

Arcturus is focused on developing infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases.

The company maintains a 'GOOD' overall Financial Health score of 2.76, suggesting resilience despite current challenges.

Arcturus developed KOSTAIVE, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved.

The company has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Under the agreement with CSL, Arcturus received an upfront payment of $200 million and is eligible for further payments based on development and commercial milestones.

In April 2025, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for Arcturus’ self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, designed for active immunization to protect against disease caused by influenza A H5N1 subtype.

Learn more about Arcturus Therapeutics' financial health at: Breaking Down Arcturus Therapeutics Holdings Inc. (ARCT) Financial Health: Key Insights for Investors

Arcturus Therapeutics Holdings Inc. (ARCT) Vision Statement of

To understand Arcturus Therapeutics' strategic direction, it's crucial to examine its mission statement, vision, and core values. These elements provide a framework for the company's goals, guiding principles, and overall aspirations. You can find more background information on Arcturus Therapeutics at: Arcturus Therapeutics Holdings Inc. (ARCT): History, Ownership, Mission, How It Works & Makes Money.

While specific details of Arcturus Therapeutics' vision statement and core values can fluctuate and are not always publicly emphasized in official communications, we can analyze their strategic goals and initiatives to infer their overarching vision and guiding principles. The company's focus on innovative RNA medicines and improving patient outcomes offers a clear insight into what drives their actions.

Here's a breakdown of key aspects derived from their public activities and statements:

Advancing RNA Medicine

Arcturus Therapeutics is deeply committed to pioneering advancements in RNA medicine. This commitment is evident through their development of various RNA technologies, including LUNAR® lipid-mediated delivery, and mRNA manufacturing. Their vision likely encompasses:

• Becoming a leader in RNA therapeutics by creating innovative technologies and expanding the applications of RNA-based treatments.
• Developing a robust pipeline of RNA medicines that address a wide range of diseases, particularly those with unmet medical needs.

Improving Patient Outcomes

A core element of Arcturus Therapeutics' vision revolves around enhancing patient outcomes. This is reflected in their pursuit of treatments for diseases such as cystic fibrosis and liver diseases. Their vision is focused on:

• Creating therapies that significantly improve the quality of life for patients.
• Addressing the root causes of diseases through targeted RNA-based interventions.
• Personalizing medicine to meet the unique needs of individual patients.

Innovation and Technology

Arcturus places a high value on innovation, constantly seeking to refine and expand its technology platforms. Evident in their continued refinement of the LUNAR® delivery platform and mRNA manufacturing processes, the vision includes:

• Driving continuous innovation in RNA technologies to improve efficacy and safety of treatments.
• Expanding the potential of RNA medicines through novel delivery methods and therapeutic applications.

Strategic Partnerships and Growth

Arcturus Therapeutics actively engages in strategic partnerships to expand its capabilities and market reach. This collaborative approach suggests a vision that includes:

• Collaborating with other leading companies and research institutions to accelerate the development and commercialization of RNA medicines.
• Expanding its global footprint to bring RNA therapies to patients worldwide.

While a formal, publicly stated vision statement may not be explicitly available, Arcturus Therapeutics' actions, technologies, and strategic priorities suggest a strong commitment to advancing RNA medicine, improving patient outcomes, and fostering innovation. These elements collectively define the essence of their vision.

Arcturus Therapeutics Holdings Inc. (ARCT) Core Values of

While specific, publicly available details on Arcturus Therapeutics' explicit mission statement, vision, and core values are limited, we can infer their guiding principles and objectives from their activities, statements, and industry focus. This analysis is based on publicly available information and aims to provide an understanding of what likely drives Arcturus Therapeutics.

From available information, here's an inferred look at what likely constitutes the core values of Arcturus Therapeutics Holdings Inc.:

Innovation and Scientific Excellence:

This value is evident in Arcturus Therapeutics' focus on developing novel RNA medicines. Their commitment to innovation is demonstrated through their proprietary delivery technologies, such as LUNAR® and UNA Oligomer technology. These technologies aim to improve the efficacy and safety of RNA-based therapies. For example, ARCALIS™ is their end-to-end messenger RNA (mRNA) medicines manufacturing solution. The company's pipeline includes mRNA-based vaccines and therapeutics targeting various diseases, reflecting a dedication to pushing the boundaries of scientific knowledge.

Patient-Centric Approach:

Arcturus Therapeutics appears dedicated to improving patient outcomes through developing innovative medicines. This patient-centric approach is reflected in their focus on addressing unmet medical needs and developing therapies for diseases with limited treatment options. For instance, their work on mRNA vaccines and therapeutics for respiratory diseases and liver diseases shows their commitment to directly impacting patient health. While specific patient advocacy programs aren't detailed in public sources, the very nature of their therapeutic development suggests a strong consideration for patient well-being and quality of life.

Collaboration and Partnership:

Arcturus Therapeutics has established collaborations with various organizations to advance its research and development efforts. These partnerships include collaborations with pharmaceutical companies, research institutions, and government agencies. For example, they have a collaboration with CSL Seqirus for the development of sa-mRNA vaccines. These collaborations enable Arcturus to leverage external expertise and resources, accelerate the development of its pipeline, and expand its reach to address global health challenges. Arcturus received approximately $175 million upfront and is eligible to receive up to $1.3 billion in future development and commercial milestones, plus royalties on future sales.

Integrity and Transparency:

While explicit statements are not available, adherence to high ethical standards and transparency in research and development are expected values for any biotechnology company. This is particularly important when dealing with novel technologies and therapies. Arcturus Therapeutics is likely committed to conducting its business with integrity, ensuring the accuracy and reliability of its data, and communicating openly with stakeholders, including investors, regulators, and the public.

Commitment to Excellence:

A dedication to excellence in all aspects of its operations, from research and development to manufacturing and commercialization, likely underpins Arcturus Therapeutics' activities. This commitment is reflected in their focus on developing high-quality products, adhering to rigorous regulatory standards, and building a strong team of scientists and professionals. This is evidenced by ARCALIS™, their end-to-end messenger RNA (mRNA) medicines manufacturing solution. Arcturus is dedicated to creating value for its shareholders, employees, and the communities it serves.

To gain more insights into Arcturus Therapeutics Holdings Inc. (ARCT), explore this resource: Exploring Arcturus Therapeutics Holdings Inc. (ARCT) Investor Profile: Who’s Buying and Why?